Safety and Efficacy of Treatments for COVID-19: A Pharmacovigilance Perspective

Authors

  • Estrada Valdés Ana Karla Faculty of Chemistry, Autonomous University of the State of Mexico (UAEMéx), Toluca, Mexico Author
  • León García Mayred Yeselin Faculty of Chemistry, Autonomous University of the State of Mexico (UAEMéx), Toluca, Mexico Author
  • Buendía Astudillo Reyna Faculty of Chemistry, Autonomous University of the State of Mexico (UAEMéx), Toluca, Mexico Author
  • Santillán Benítez Jonnathan Guadalupe Faculty of Chemistry, Autonomous University of the State of Mexico (UAEMéx), Toluca, Mexico Author

DOI:

https://doi.org/10.47363/JVRR/2024(5)162

Keywords:

Pharmacological Alternatives, Antivirals, Derived Risks, Risk Groups, Therapies, Effectiveness of Treatments

Abstract

Objective: COVID-19 has generated the development of safe and effective against viral disease. In this context, the Pharmacovigilance emerges as a crucial tool to provide detailed follow-up of treatments administered to infected patients. The objective of this review is to understand the role and progress of pharmacovigilance in the COVID-19 pandemic by supporting healthcare professionals and providing information about possible Adverse Drug Reactions in patients.

Methods: A review of Pharmacovigilance related to COVID-19 was conducted, addressing aspects such as the monitoring of Adverse Drug Reactions, virus structure and therapeutic advances, since 2019 to 2022, databases such as Pubmed, Scielo, Science Direct, JAMA y Redalyc were used, analyzing clinical trials, observational studies and case reports to assess the safety of drugs used in the treatments of COVID-19.

Results: Pharmacovigilance provides information of risk and benefits of drugs. Reports have been implemented to detect Adverse Drug Reactions and seek pharmacological alternatives to reduce serius symptoms and complications.

Conclusion: Pharmacovigilance in the COVID-19 pandemic requires efficient communication between healthcare professionals and pharmacists ensuring quality treatments and detecting possible Adverse Drug Reactions.

Author Biographies

  • Estrada Valdés Ana Karla, Faculty of Chemistry, Autonomous University of the State of Mexico (UAEMéx), Toluca, Mexico

    Jonnathan Guadalupe Santillán-Benítez, Faculty of Chemistry, Autonomous University of the State of Mexico (UAE Méx), Toluca, Mexico.

  • León García Mayred Yeselin, Faculty of Chemistry, Autonomous University of the State of Mexico (UAEMéx), Toluca, Mexico

    Faculty of Chemistry, Autonomous University of the State of Mexico (UAEMéx), Toluca, Mexico

  • Buendía Astudillo Reyna, Faculty of Chemistry, Autonomous University of the State of Mexico (UAEMéx), Toluca, Mexico

    Faculty of Chemistry, Autonomous University of the State of Mexico (UAEMéx), Toluca, Mexico

  • Santillán Benítez Jonnathan Guadalupe, Faculty of Chemistry, Autonomous University of the State of Mexico (UAEMéx), Toluca, Mexico

    Faculty of Chemistry, Autonomous University of the State of Mexico (UAEMéx), Toluca, Mexico 

Downloads

Published

2024-02-28

Issue

Vol. 5 No. 1 (2024): Volume 5, Issue 1

Section

Articles